Literature DB >> 21672190

Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study.

Carlos Iribarren1, Bruce H Phelps, Jeanne A Darbinian, Edward R McCluskey, Charles P Quesenberry, Evangelos Hytopoulos, Joseph H Vogelman, Norman Orentreich.   

Abstract

BACKGROUND: Angiogenesis is up-regulated in myocardial ischemia. However, limited data exist assessing the value of circulating angiogenic biomarkers in predicting future incidence of acute myocardial infarction (AMI). Our aim was to examine the association between circulating levels of markers of angiogenesis with risk of incident acute myocardial infarction (AMI) in men and women.
METHODS: We performed a case-control study (nested within a large cohort of persons receiving care within Kaiser Permanente of Northern California) including 695 AMI cases and 690 controls individually matched on age, gender and race/ethnicity.
RESULTS: Median [inter-quartile range] serum concentrations of vascular endothelial growth factor-A (VEGF-A; 260 [252] vs. 235 [224] pg/mL; p = 0.01) and angiopoietin-2 (Ang-2; 1.18 [0.66] vs. 1.05 [0.58] ng/mL; p < 0.0001) were significantly higher in AMI cases than in controls. By contrast, endothelium-specific receptor tyrosine kinase (Tie-2; 14.2 [3.7] vs. 14.0 [3.1] ng/mL; p = 0.07) and angiopoietin-1 levels (Ang-1; 33.1 [13.6] vs. 32.5 [12.7] ng/mL; p = 0.52) did not differ significantly by case-control status. After adjustment for educational attainment, hypertension, diabetes, smoking, alcohol consumption, body mass index, LDL-C, HDL-C, triglycerides and C-reactive protein, each increment of 1 unit of Ang-2 as a Z score was associated with 1.17-fold (95 percent confidence interval, 1.02 to 1.35) increased odds of AMI, and the upper quartile of Ang-2, relative to the lowest quartile, was associated with 1.63-fold (95 percent confidence interval, 1.09 to 2.45) increased odds of AMI.
CONCLUSIONS: Our data support a role of Ang-2 as a biomarker of incident AMI independent of traditional risk factors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21672190      PMCID: PMC3124417          DOI: 10.1186/1471-2261-11-31

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  33 in total

1.  AUTOMATED MULTIPHASIC SCREENING AND DIAGNOSIS.

Authors:  M F COLLEN; L RUBIN; J NEYMAN; G B DANTZIG; R M BAER; A B SIEGELAUB
Journal:  Am J Public Health Nations Health       Date:  1964-05

2.  Periodic health evaluations: the multiphasic approach.

Authors:  M F Collen
Journal:  Internist       Date:  1981-05       Impact factor: 0.743

3.  Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel.

Authors:  K G Peters
Journal:  Circ Res       Date:  1998-08-10       Impact factor: 17.367

4.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

5.  Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF).

Authors:  Richard P Visconti; Charlene D Richardson; Thomas N Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-04       Impact factor: 11.205

6.  Ethnic disparities in diabetic complications in an insured population.

Authors:  Andrew J Karter; Assiamira Ferrara; Jennifer Y Liu; Howard H Moffet; Lynn M Ackerson; Joe V Selby
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

Review 7.  Arteriogenesis: the development and growth of collateral arteries.

Authors:  Armin Helisch; Wolfgang Schaper
Journal:  Microcirculation       Date:  2003-01       Impact factor: 2.628

Review 8.  Human studies of angiogenic gene therapy.

Authors:  Rajesh Gupta; Jörn Tongers; Douglas W Losordo
Journal:  Circ Res       Date:  2009-10-09       Impact factor: 17.367

9.  Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Stefanie Dimmeler; Christian W Hamm; Eric Boersma; Andreas M Zeiher; Maarten L Simoons
Journal:  Circulation       Date:  2003-02-04       Impact factor: 29.690

10.  Prospective association of vascular endothelial growth factor-A (VEGF-A) with coronary heart disease mortality in southeastern New England.

Authors:  Charles B Eaton; Robert Gramling; Donna R Parker; Mary B Roberts; Bing Lu; Paul M Ridker
Journal:  Atherosclerosis       Date:  2008-02-07       Impact factor: 5.162

View more
  18 in total

Review 1.  Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.

Authors:  Panagiotis Tsibouris; Erasmia Vlachou; Peter Edward Thomas Isaacs
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

2.  Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study.

Authors:  Panagiotis Tsibouris; Mark T Hendrickse; Panagiota Mavrogianni; Peter Et Isaacs
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 3.  Circulating microRNAs as novel and sensitive biomarkers of acute myocardial Infarction.

Authors:  Chuanwei Li; Fang Pei; Xiaoshan Zhu; Dayue D Duan; Chunyu Zeng
Journal:  Clin Biochem       Date:  2012-07       Impact factor: 3.281

Review 4.  Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes.

Authors:  A M Isidori; M A Venneri; D Fiore
Journal:  J Endocrinol Invest       Date:  2016-06-25       Impact factor: 4.256

5.  Cardioprotective effects of adipokine apelin on myocardial infarction.

Authors:  Bao-Hai Zhang; Cai-Xia Guo; Hong-Xia Wang; Ling-Qiao Lu; Ya-Jie Wang; Li-Ke Zhang; Feng-He Du; Xiang-Jun Zeng
Journal:  Heart Vessels       Date:  2013-10-19       Impact factor: 2.037

6.  Serial plasma levels of angiogenic factors in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Bo Hyun Kim; Young-Guk Ko; Ae-Young Her; Jung-Sun Kim; Ki-Chul Hwang; Dong-Ho Shin; Byeong-Keuk Kim; Donghoon Choi; Jong-Won Ha; Myeong-Ki Hong; Yangsoo Jang
Journal:  Korean Circ J       Date:  2012-07-26       Impact factor: 3.243

7.  Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice.

Authors:  Thomas L Theelen; Jari P Lappalainen; Judith C Sluimer; Erika Gurzeler; Jack P Cleutjens; Marion J Gijbels; Erik A L Biessen; Mat J A P Daemen; Kari Alitalo; Seppo Ylä-Herttuala
Journal:  Atherosclerosis       Date:  2015-06-03       Impact factor: 5.162

8.  Association of serum angiopoietin-1, angiopoietin-2 and angiopoietin-2 to angiopoietin-1 ratio with heart failure in patients with acute myocardial infarction.

Authors:  Shaomin Chen; Lijun Guo; Baoxia Chen; Lijie Sun; Ming Cui
Journal:  Exp Ther Med       Date:  2013-01-14       Impact factor: 2.447

9.  Changes of serum angiogenic factors concentrations in patients with diabetes and unstable angina pectoris.

Authors:  Chun Gui; Shi-kang Li; Qin-ling Nong; Fang Du; Li-guang Zhu; Zhi-yu Zeng
Journal:  Cardiovasc Diabetol       Date:  2013-02-19       Impact factor: 9.951

10.  MiRNAs as biomarkers of myocardial infarction: a meta-analysis.

Authors:  Chao Cheng; Qiang Wang; Wenjie You; Manhua Chen; Jiahong Xia
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.